文献速递头颈外科

多激酶抑制剂索拉非尼与舒尼替尼作为头颈癌细胞系放射增敏剂的研究

Multikinase inhibitors sorafenib and sunitinib as radiosensitizers in head and neck cancer cell lines.
PubMed 文献 · Head Neck · 2017-02-21

本研究在培养的头颈鳞状细胞癌细胞系中,联合使用多激酶抑制剂索拉非尼或舒尼替尼与照射,通过凋亡与克隆形成实验评估放射增敏效应,并用蛋白质印迹确认。结果显示两药与照射联用对克隆存活呈强且超加性的抗肿瘤作用,增强照射诱导的凋亡并抑制照射后磷酸化ERK表达;复发患者肿瘤组织pERK水平显著低于无复发患者。作者提出进一步评估索拉非尼与舒尼替尼作为头颈鳞癌潜在放射增敏剂。

要点

  • 索拉非尼或舒尼替尼联合照射对头颈鳞癌细胞克隆存活呈强且超加性抗肿瘤作用。
  • 激酶抑制增强照射诱导的凋亡率并抑制照射后磷酸化ERK表达。
  • 复发头颈鳞癌患者的pERK水平显著低于无复发患者。

核心结论

  • 作者提出进一步评估索拉非尼与舒尼替尼作为头颈鳞癌治疗中潜在放射增敏剂。

研究设计与样本

  • 研究在培养的头颈鳞状细胞癌细胞系中进行,给予多激酶抑制剂后照射,采用膜联蛋白V凋亡实验与克隆形成实验评估放射增敏效应,并用蛋白质印迹确认,另用人类头颈鳞癌组织芯片调查活化ERK表达。

主要发现

  • 基于联合指数,照射与两种抑制剂联用对克隆存活表现出强且超加性的抗肿瘤作用。
  • 激酶抑制增强了照射诱导的凋亡率,并抑制照射后磷酸化ERK表达。
  • 复发头颈鳞癌患者的细胞外信号调节激酶磷酸化(pERK)水平显著低于无复发患者。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Radioresistance is a common feature of head and neck squamous cell carcinoma (HNSCC). We previously showed that the irradiation- activated vascular endothelial growth factor (VEGF)-extracellular signal-regulated kinase (ERK)-axis is fundamental for the survival of resistant tumors. In this study, we examined if treatment with potent multikinase (MK) inhibitors, sorafenib and sunitinib, could radiosensitize tumor cells. METHODS: Cultured HNSCC cell lines were treated with inhibitors and subsequently irradiated. Radiosensitizing effects were functionally assessed by annexin-V apoptosis and clonogenic assays and confirmed by Western blot. Additionally, we surveyed human HNSCC tissue microarrays (TMAs) for activated ERK expression. RESULTS: Based on combination indexes, we found that combining irradiation with both inhibitors exerted strong and supra-additive antitumor effects on clonogenic survival. Kinase inhibition enhanced irradiation-induced apoptotic rates and inhibited postradiogenic phospho-ERK-expression. Patients with recurrent HNSCC displayed significantly lower extracellular signal-regulated kinase phosphorylation (pERK) levels than relapse-free patients. CONCLUSION: We propose further evaluation of sorafenib and sunitinib as potential radiosensitizing agents in HNSCC treatment. © 2017 Wiley Periodicals, Inc. Head Neck 39: 623-632, 2017.

来源:Head Neck,查看原文。版权归原作者所有。

引用

  1. Affolter A, Samosny G, Heimes AS, et al. Multikinase inhibitors sorafenib and sunitinib as radiosensitizers in head and neck cancer cell lines. Head Neck. 2017. PMID: 28221700. doi:10.1002/hed.24557

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。